Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study
dc.contributor.author | Xie, Mingchao | |
dc.contributor.author | Chen, Yuanbin | |
dc.contributor.author | Hotta, Katsuyuki | |
dc.contributor.author | Poltoratskiy, Artem | |
dc.contributor.author | Hochmair, Maximilian J. | |
dc.contributor.author | ÖZGÜROĞLU, Mustafa | |
dc.contributor.author | Ji, Jun Ho | |
dc.contributor.author | Statsenko, Galina | |
dc.contributor.author | Voitko, Oleksandr | |
dc.contributor.author | Conev, Nikolay V. | |
dc.contributor.author | Bondarenko, Igor | |
dc.contributor.author | Mann, Helen | |
dc.contributor.author | Bischoff, Helge | |
dc.contributor.author | Paz-Ares, Luis | |
dc.contributor.author | Dalvi, Tapashi | |
dc.contributor.author | Chugh, Priti | |
dc.contributor.author | Shrestha, Yashaswi | |
dc.contributor.author | Goldman, Jonathan W. | |
dc.contributor.author | Garassino, Marina Chiara | |
dc.date.accessioned | 2023-02-21T08:22:53Z | |
dc.date.available | 2023-02-21T08:22:53Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Goldman J. W., Garassino M. C., Chen Y., Hotta K., Poltoratskiy A., Hochmair M. J., ÖZGÜROĞLU M., Ji J. H., Statsenko G., Voitko O., et al., "Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study", ONCOLOGY RESEARCH AND TREATMENT, cilt.45, sa.SUPPL 3, ss.161, 2022 | |
dc.identifier.issn | 2296-5270 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_1999cb12-f201-4e9b-973a-42b682a88ccf | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/186606 | |
dc.language.iso | eng | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Sağlık Bilimleri | |
dc.title | Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study | |
dc.type | Makale | |
dc.relation.journal | ONCOLOGY RESEARCH AND TREATMENT | |
dc.contributor.department | University of California System , , | |
dc.identifier.volume | 45 | |
dc.identifier.issue | SUPPL 3 | |
dc.identifier.startpage | 161 | |
dc.identifier.endpage | 161 | |
dc.contributor.firstauthorID | 4085128 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Makale [92796]